New Treatment of Common Wart
ConditionCommon Warts (Verruca Vulgaris)
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorSohag University
About this trial
this study aims to compare the efficacy and safety of platelet rich fibrin injection versus intralesional vitamin D injection in the treatmentof common warts. PRF, as an autologous biological material , may enhance tissue regeneration and immune response.
Eligibility criteria
Qualifiers
- Age more than or equal to 18 years
Clinically and dermoscopically confirmed Common warts of both sex
patient not receiving previous treatment at least one month before recruitment in our study
Single or multiple lesions suitable for injection.
Disqualifiers
Chronic Systemic desise (DM , HTN , Autoimmune , immunosuppressive disorders eg , lupus , renal or hepatic failure ) or Hematologic Conditions (anemia : hemoglobin level below 10 g/dl , thrombocytopenia : platelet count below 150,000 /µL ) Infectious Diseases , Local bacterial or fungal infection at the lesions .
Trial design
Treatments tested in this trial
- PRF group
- Vitamin D
Treatment groups
70 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov